SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases & Vaccines
- Oncology & Hematology
- Pediatrics
- Rare Diseases
- View All
Obesity
"Advancing obesity and obesity-related trials with patients at the center of development.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS
- Real World & Healthcare Data
- Health Data Apps & AI
- Analytics Research Accelerator
- Expert Ecosystem
- AI Patient & HCP Profiling- Commercial
- AI Patient & Provider Profiling- Med Affairs
- AI Patient & HCP Profiling- Healthcare
- Natural Language Processing
- Market Access Insights
- Direct-to-Patient Research
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI®
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESBlog
Semaglutide LoE in India: A rare opportunity demanding a new playbook
Oct 15, 2025
India’s Semaglutide Loss of Exclusivity (LoE) marks a strategic inflection point, combining scale, urgency, and ambiguity in a market still forming. With 150M+ addressable patients, early LoE timing, and a digitally connected self-pay ecosystem, India is not just a launch market, it’s a blueprint for global obesity care.
Semaglutide’s LoE in India is unlikely to follow the traditional generics playbook. The market is still being shaped, patient journeys are evolving, and therapy adoption is influenced as much by patient pull as by prescriber push. The compressed innovator launch window, coupled with rising patient awareness and evolving diagnostic frameworks, creates a strategic white space, one that demands reinvention, not replication.
India’s Semaglutide LoE: A catalyst for global market shapingIndia’s early LoE timing, vast self-pay population, and digitally connected ecosystem make it a strategic inflection point for Semaglutide’s post-patent journey. This is not just a domestic event, it’s a global signal.
India’s LoE moment will shape not only domestic outcomes but global norms for pricing, access, and category creation.
1IQVIA analysis from World Obesity Observatory; 2IQVIA’s internal affordability matrix
Semaglutide LoE in India: A playbook unlike any other
Semaglutide’s LoE in India is not likely to follow the traditional generics trajectory seen in previous cardio- metabolic categories. Unlike past LoEs, this one unfolds in a market still being shaped, with compressed innovator presence, evolving guidelines, and rising patient influence.
This is not a moment to replicate past LoE playbooks, it’s a moment to redefine them.
The Size of the prize: Obesity set to become a top 5 disease area in India
Semaglutide’s LoE is unlocking one of the most significant growth opportunities in the Indian pharmaceutical market, with obesity pharmacotherapy poised to become a top 5 disease area by 2030.
This is not just a growth opportunity, it’s a category-defining moment for chronic care in India.
3,4IQVIA analysis; 5IQVIA estimates from proprietary datasets and secondary research
Generics in Semaglutide LoE: From tactical launches to strategic market shaping
Semaglutide’s LoE presents a rare opportunity for generics, but winning will require reinvention, not replication. The traditional share-of-voice model won’t suffice in a market defined by fragmentation, patient influence, and therapy complexity.
Generics won’t just compete; they’ll co-create the category. Strategic clarity and execution agility will define the winners.
Innovators in Semaglutide LoE: Defending leadership in a market still forming
Semaglutide’s LoE in India presents a compressed launch window for innovators, but also a strategic opening.
With the market still taking shape, innovators must pivot from tactical defense to agile, differentiated market shaping.
Winning post-LoE will require precision, agility, and a compelling value narrative — not legacy strength but adaptive leadership.
Conclusion: India’s Semaglutide LoE: A strategic blueprint for global obesity care
India’s Semaglutide LoE is not just a market event, it’s a strategic inflection point with global implications.
As India enters a precedent-setting phase in obesity pharmacotherapy, country leaders must ask:
This is not a moment to replicate past LoE playbooks, it’s a moment to redefine them.
Want to access the full white paper? Register your interest here.